Showing results (361-370 of 418) with videos related to

Sort By:
Pageof 42
Cancer Treatment Reviews|April 11, 2024
Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary groupMaria Chiara Zatelli, Antongiulio Faggiano, Antonella Argentiero, et al.
The Lancet. Oncology|July 13, 2016
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort studyMarina Bagnoli, Silvana Canevari, Daniela Califano, et al.
Eclinicalmedicine|September 19, 2025
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysisSara Oresti, Fabio Salomone, Antonio Nuccio, et al.
Oncotarget|March 9, 2018
Frequent <i>NRG1</i> fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expressionDomenico Trombetta, Paolo Graziano, Aldo Scarpa, et al.
BMJ Open|October 21, 2021
Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare systemSilvia Riva, Laura Arenare, Massimo Di Maio, et al.
Lung Cancer (Amsterdam, Netherlands)|April 5, 2016
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational studyTiziana Vavalà, Alessandro Follador, Marcello Tiseo, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2022
Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequencesFabrizio Tabbò, Lucia Anna Muscarella, Elisa Gobbini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trialCesare Gridelli, Fortunato Ciardiello, Ciro Gallo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2012
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancerMassimo Di Maio, Natasha B Leighl, Ciro Gallo, et al.
Clinical Genitourinary Cancer|October 5, 2023
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective AnalysisChiara Pisano, Fabio Turco, Elena Arnaudo, et al.
Pageof 42